Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Biomea Fusion Inc BMEA

Healthcare Biotechnology
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It’s lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone... see more

Current News (NDAQ:BMEA)

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

GlobeNewswire 2 days ago

Biomea Fusion to Participate at Upcoming Investor Conferences

GlobeNewswire February 19, 2026

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

GlobeNewswire January 12, 2026

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 17, 2025

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

GlobeNewswire December 9, 2025

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

GlobeNewswire December 5, 2025

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

GlobeNewswire December 1, 2025

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 1, 2025

Biomea Fusion to Participate at Upcoming Investor Conferences

GlobeNewswire November 24, 2025
View More News ››

Opinion & Analysis (NDAQ:BMEA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BMEA)

BMEA News and Upgrade just out with 40$ price target CC Toda

BMEA News and Upgrade just out with 40$ price target CC Today at 4pm
10QKing - September 26, 2024
View more Bullboard ››

Atlas Salt Inc.

Atlas Salt Inc.

Atlas Salt Inc. engages in the evaluation, exploration and development of mineral properties in Newfoundland and Labrador ...
View More »

Podcasts